American Pharmaceutical Partners Launches Enhanced Corporate Web Site
Posted on: Tuesday, 30 August 2005, 06:00 CDT
SCHAUMBURG, Ill., Aug. 30 /PRNewswire-FirstCall/ -- American Pharmaceutical Partners, Inc. , today said that an enhanced version of its Web site, http://www.appdrugs.com/, has been launched. The redesigned, user-friendly site gives a comprehensive view of the company and contains an expanded range of informational topics.
The new site was developed to improve critical information flow with pharmacists, doctors and patients and promote communication with shareholders and other interested parties. Web site visitors can view information about the company's patient safety initiatives and product offering alphabetically and by therapeutic class. The Web site provides related links to APP's proprietary drug division, Abraxis Oncology (http://www.abraxisoncology.com/) and ABRAXANE(TM) (http://www.abraxane.com/), which includes extensive information on the product for both healthcare professionals as well as patients. The site also features an updated investor relations section for existing and prospective investors, with stock charts, statistics, bios of the senior management team and board of directors, news releases and SEC filings.
About American Pharmaceutical Partners
American Pharmaceutical Partners, Inc. is a specialty drug company that develops, manufactures and markets injectable pharmaceutical products, focusing on the oncology, anti-infective and critical care markets. Abraxis Oncology, the proprietary division of APP, is devoted entirely to developing and promoting innovative, next-generation cancer therapies such as ABRAXANE(TM), recently launched for the treatment of metastatic breast cancer. For more information, visit APP's website at http://www.appdrugs.com/ and http://www.abraxisoncology.com/.
Contacts: American Pharmaceutical Partners, Inc. Nicole Williams Executive Vice President & CFO (847) 969-2700 Rob Whetstone/Robert Jaffe PondelWilkinson Inc. (310) 279-5963
American Pharmaceutical Partners, Inc.
CONTACT: Nicole Williams of American Pharmaceutical Partners, Inc. ofExecutive Vice President & CFO, +1-847-969-2700; or Rob Whetstone, or RobertJaffe, both of PondelWilkinson Inc., +1-310-279-5963, for AmericanPharmaceutical Partners, Inc.
Web site: http://www.abraxane.com/
Web site: http://www.abraxisoncology.com/
Web site: http://www.appdrugs.com/
Source: PRNewswire-FirstCall
Related Articles
- American Pharmaceutical Partners Adds to Its Broad Oncology Portfolio With the Approval of Mitoxantrone Injection, USP
- American Bioscience and American Pharmaceutical Partners to Present Six Abstracts on Applications of Nanoparticle Albumin Bound (Nab(TM)) Tumor Targeting Technology at the 97th American Association of Cancer Research Annual Meeting
- American Pharmaceutical Partners to Present at the Lazard Capital Markets Life Sciences Conference on November 30
- American Pharmaceutical Partners to Present at the CIBC 16th Annual Healthcare Conference on November 8
- American Pharmaceutical Partners to Present at The Bear Stearns 18th Annual Healthcare Conference on September 12
- American Pharmaceutical Partners Reports on Melrose Park, Il Operations and Provides Update on $120 Million Company-Wide Facility Upgrade and Expansion Initiative
- American Pharmaceutical Partners Reports on Status of Ceftriaxone Product Approval
- American Pharmaceutical Partners Announces Presentation of ABRAXANE(TM) Survival Data at 22nd Annual Miami Breast Cancer Conference
- American Pharmaceutical Partners Presents Data on High Dose Weekly ABRAXANE(TM) in Taxane-Refractory Metastatic Breast Cancer Patients
 |
 |
User Comments (0)
RSS Feeds